Paralel Advisors LLC Buys Shares of 185,831 Amneal Pharmaceuticals, Inc. $AMRX

Paralel Advisors LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 185,831 shares of the company’s stock, valued at approximately $3,217,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMRX. Rubric Capital Management LP grew its stake in Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after buying an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after buying an additional 81,546 shares during the last quarter. Morgan Stanley raised its stake in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after acquiring an additional 558,877 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after acquiring an additional 136,662 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $17.44 on Monday. The business’s 50-day moving average price is $17.76 and its 200 day moving average price is $14.96. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 35.59 and a beta of 1.24. Amneal Pharmaceuticals, Inc. has a 52 week low of $9.44 and a 52 week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the sale, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 413,016 shares of company stock worth $7,216,567 in the last three months. Company insiders own 17.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMRX. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $19.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.